Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
被引用次数：144 相关文章

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - infona.pl
Mutations in the epidermal growth factor receptor (EGFR) gene are associated with
increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine …

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa… - Lung cancer …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose Mutations in the epidermal growth factor receptor (EGFR) gene are associated with
increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine …

[引用][C] Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N SUNAGA - Lung Cancer, 2007 - cir.nii.ac.jp
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small
cell lung cancer with EGFR mutations, irrespective of previous chemotherapy | CiNii Research …

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa, N Yanagitani, H Iijima… - Lung …, 2007 - lungcancerjournal.info
Purpose Mutations in the epidermal growth factor receptor (EGFR) gene are associated with
increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine …

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa, N Yanagitani… - Lung Cancer …, 2007 - europepmc.org
Purpose Mutations in the epidermal growth factor receptor (EGFR) gene are associated with
increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine …

[引用][C] Phase ii prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N SUNAGA, Y TOMIZAWA, R SAITO… - Lung …, 2007 - pascal-francis.inist.fr
Phase ii prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small
cell lung cancer with EGFR mutations, irrespective of previous chemotherapy CNRS Inist …

[引用][C] Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N SUNAGA - Lung Cancer, 2007 - cir.nii.ac.jp
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small
cell lung cancer with EGFR mutations, irrespective of previous chemotherapy | CiNii Research …

[引用][C] Phase ii prospective study of the efficacy of gefitinib for the treatment of stage III

N SUNAGA, Y TOMIZAWA, N YANAGITANI, H IIJIMA… - Lung cancer, 2007 - Elsevier